Medical News Today (Free subscription) | 11 hours ago
Medarex, Inc. (Nasdaq: MEDX) announced that nine clinical abstracts for ipilimumab, an investigational anti-CTLA-4 antibody, in melanoma are scheduled to be the subject of presentations at the 33rd Congress of the European Society for Medical Oncology (ESMO) being held September 12-16, 2008 in Stockholm.
PR News Wire (Free subscription) | 02/09/2008
PRINCETON, N.J., Sept. 2 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: ) announced today that it is scheduled to present at the Thomas Weisel Partners Healthcare Conference at 9:10 a.m. Eastern Time on Thursday, September 4, 2008. The event will be webcast live and will be available in the Investor Relations section of the Medarex website at . An archived edition of the presentation will be available following...
Medical News Today (Free subscription) | 13/08/2008
Medarex, Inc. (Nasdaq: MEDX) announced that its partner MedImmune, Inc. has initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus (SLE or lupus). MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human Antibody Development System(R).
PR News Wire (Free subscription) | 12/08/2008
Medarex to Receive Milestone Payment from MedImmune PRINCETON, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: ) announced today that its partner MedImmune, Inc. has initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus (SLE or lupus). MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human Antibody Development...
Medical News Today (Free subscription) | 06/08/2008
Medarex, Inc. (Nasdaq: MEDX) announced the allowance of an investigational new drug application (IND) filed with the U.S. Food & Drug Administration (FDA) for MDX-1105, for the treatment of patients with selected advanced or recurrent solid tumors, specifically renal cell carcinoma, melanoma, non-small cell lung cancer or epithelial ovarian cancer.
PR News Wire (Free subscription) | 05/08/2008
PRINCETON, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: ) announced today its financial results for the quarter ended June 30, 2008. Medarex's net loss for the quarter ended June 30, 2008 was $53.1 million, or ($0.42) per share as compared to a net loss of $41.0 million, or ($0.32) per share for the second quarter of 2007. Included in the 2008 results was a non-cash charge of $6.0...
Red Orbit (Free subscription) | 23/07/2008
PRINCETON, N.J., July 23 /PRNewswire-FirstCall/ -- Medarex, Inc. today announced that it has received a milestone payment of an undisclosed amount from its licensing partner, Centocor R&D Inc., for the acceptance of an Investigational New Drug Application (IND) to the U.S.
PR News Wire (Free subscription) | 23/07/2008
PRINCETON, N.J., July 23 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: ) today announced that it has received a milestone payment of an undisclosed amount from its licensing partner, Centocor R&D Inc., for the acceptance of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for an undisclosed antibody. The antibody was generated by Medarex's UltiMAb Human...
Red Orbit (Free subscription) | 16/07/2008
PRINCETON, N.J., July 16 /PRNewswire-FirstCall/ -- BioWa, Inc. and Medarex, Inc.
PR News Wire (Free subscription) | 16/07/2008
PRINCETON, N.J., July 16 /PRNewswire-FirstCall/ -- BioWa, Inc. and Medarex, Inc. (Nasdaq: ) announced today that they have entered into a license agreement which provides Medarex with the first ever access to BioWa's COMPLEGENT(TM) Technology for enhancing the complement-dependent cytotoxicity (CDC) of select Medarex therapeutic antibodies. The license grants Medarex non-exclusive rights to research,...
www.OSIR.org.in (Free subscription) | 10/07/2008
PRINCETON, N.J., July 10 /PRNewswire-FirstCall/ — Medarex, Inc. MEDX today provided a detailed overview of the company’s strategy, strength in research discovery and antibody development, and the multiple opportunities Medarex is engaged in for Source: news.moneycentral.msn.com Jodrell Bank radiotelescope spared the axe - ZDNet UKThe iconic radiotelescope at the Jodrell Bank Centre for Astrophysics,...
PR News Wire (Free subscription) | 10/07/2008
PRINCETON, N.J., July 10 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: ) today provided a detailed overview of the company's strategy, strength in research discovery and antibody development, and the multiple opportunities Medarex is engaged in for creating long-term value. In addition, comprehensive updates on current and future antibody programs as well as updated 2008 financial guidance were...
The Street (Free subscription) | 10/07/2008
Why telaprevir dosing is key for Vertex; where in the world is Medarex CEO Howard Pien; what updates to look for in biotech earnings; and more.
The Earth Times Online Newspaper (Free subscription) | 07/07/2008
PRINCETON, N.J., July 7 -- Medarex, Inc. (Nasdaq: MEDX) invites investors, the media and the general public to listen to a live webcast of its 2008 R&D Day event. The webcast will begin on Thursday, July 10, 2008 at
PR News Wire (Free subscription) | 18/06/2008
PRINCETON, N.J., June 18 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: ) announced today that it is scheduled to present at the Jefferies Second Annual Healthcare Conference at 11:15 a.m. Eastern Time on Wednesday, June 25, 2008. The event will be webcast live and will be available in the Investor Relations section of the Medarex website at . An archived edition of the presentation will be available following...
